EGFR and dermatological toxicity: Even if considering only trials with similar settings (mCRC treated with EGFR inhibitors) the rates of grade ≥ 2 skin toxicity in the preemptive arms are considerably lower in previous studies with 20% [5], 21.3% [12] and 29% [3]) and could not be reproduced in the present trial.